Dobs4ever
10-08-2009, 01:52 PM
I just received this info and wanted to share this information with all dog loving friends!
FDA Approves First Canine Cancer Therapy=
Pfizer Animal Health Receives Approval for PALLADIATM
MONTREAL--(BUSINESS WIRE)--Pfizer Animal Health today announced that the U.
S. Food and Drug Administration (FDA) has approved the first canine cancer
therapy in the U.S. =E2=80=93 PALLADIATM (toceranib phosphate) which
was developed by Pfizer to treat mast cell tumors in dogs. Pfizer made
the announcement to veterinarians attending the 2009 American College of
Veterinary Internal Medicine (ACVIM) Forum and Canadian Veterinary Medical
Association Convention.
Pfizer Animal Health is proud to bring the first canine cancer therapy
approved by the FDA to U.S. specialists, their patients and caregivers,
said George Fennell, vice president, Companion Animal Division,
Pfizer Animal Health. In the weeks and months ahead, Pfizer will
introduce PALLADIA to boarded specialists to expand the body of clinical
experience with this new therapy. The experience gained during this time
will
enable us to support veterinarians more effectively when we make the
product
available for purchase in early 2010, Fennell said.
Pet caregivers should continue to consult with their local veterinarians
about
options for their dogs with cancer, who may then refer appropriate cases
to specialists for treatment with PALLADIA.
A new option to treat canine mast cell tumors
According to the Morris Animal Foundation, cancer is a leading cause of
death
in dogs.
Pfizer Animal Health estimates 1.2 million new canine cancer cases are
reported in
the U.S. every year. 2 Mast cell tumors are the second most common tumor
type and are often seen as lumps in the skin. These tumors are classified as
grade I, II or III, with grade III being the most severe. If not treated,
they can spread to other parts of the body including lymph nodes.
Prescription- only PALLADIA is an oral therapy indicated to treat Patnaik
grade II or III recurrent cutaneous mast cell tumors with or without
regional
lymph node involvement. PALLADIA belongs to the tyrosine kinase inhibitor
(TKI) class of compounds. It works by blocking the activity of key receptors
important for the development of blood vessels that supply tumors, as well
as receptors critical for tumor survival.
PALLADIA is an exciting, new treatment option for dogs with mast
cell tumors, said Cheryl London, DVM, PhD, board certified medical
oncologist and associate professor at The Ohio State University College of
Veterinary Medicine.
At the completion of a PALLADIA clinical study, approximately 60%
of dogs had their tumors disappear, shrink or stop growing. Also, we
determined
that dogs whose tumors responded to PALLADIA experienced an improved
quality of life, said Dr. London, who has helped Pfizer Animal Health
Veterinary Medicine Research & Development to develop PALLADIA
since 2000.
Further Information about PALLADIA
PALLADIA can be administered in a veterinary clinic or in the home by a dogs
caregiver. PALLADIA is not for human use and is only available
in the U.S. Adverse events with PALLADIA can be serious but most are mild to
moderate and are generally manageable. The most common side effects of
PALLADIA involve the gastrointestinal tract and signs include diarrhea,
decreased appetite, lethargy and vomiting. Life-threatening adverse events
are
rare but possible and early recognition is critical. Children should not
come
in contact with PALLADIA. In addition, all individuals, including children
and pregnant women, should avoid direct contact with broken or partially-
dissolved PALLADIA tablets or biological waste from dogs treated with
PALLADIA. For specific dosing and prescribing information, visit
<
http://www.palladia -pi.com/> www.palladia- pi.com
FDA Approves First Canine Cancer Therapy=
Pfizer Animal Health Receives Approval for PALLADIATM
MONTREAL--(BUSINESS WIRE)--Pfizer Animal Health today announced that the U.
S. Food and Drug Administration (FDA) has approved the first canine cancer
therapy in the U.S. =E2=80=93 PALLADIATM (toceranib phosphate) which
was developed by Pfizer to treat mast cell tumors in dogs. Pfizer made
the announcement to veterinarians attending the 2009 American College of
Veterinary Internal Medicine (ACVIM) Forum and Canadian Veterinary Medical
Association Convention.
Pfizer Animal Health is proud to bring the first canine cancer therapy
approved by the FDA to U.S. specialists, their patients and caregivers,
said George Fennell, vice president, Companion Animal Division,
Pfizer Animal Health. In the weeks and months ahead, Pfizer will
introduce PALLADIA to boarded specialists to expand the body of clinical
experience with this new therapy. The experience gained during this time
will
enable us to support veterinarians more effectively when we make the
product
available for purchase in early 2010, Fennell said.
Pet caregivers should continue to consult with their local veterinarians
about
options for their dogs with cancer, who may then refer appropriate cases
to specialists for treatment with PALLADIA.
A new option to treat canine mast cell tumors
According to the Morris Animal Foundation, cancer is a leading cause of
death
in dogs.
Pfizer Animal Health estimates 1.2 million new canine cancer cases are
reported in
the U.S. every year. 2 Mast cell tumors are the second most common tumor
type and are often seen as lumps in the skin. These tumors are classified as
grade I, II or III, with grade III being the most severe. If not treated,
they can spread to other parts of the body including lymph nodes.
Prescription- only PALLADIA is an oral therapy indicated to treat Patnaik
grade II or III recurrent cutaneous mast cell tumors with or without
regional
lymph node involvement. PALLADIA belongs to the tyrosine kinase inhibitor
(TKI) class of compounds. It works by blocking the activity of key receptors
important for the development of blood vessels that supply tumors, as well
as receptors critical for tumor survival.
PALLADIA is an exciting, new treatment option for dogs with mast
cell tumors, said Cheryl London, DVM, PhD, board certified medical
oncologist and associate professor at The Ohio State University College of
Veterinary Medicine.
At the completion of a PALLADIA clinical study, approximately 60%
of dogs had their tumors disappear, shrink or stop growing. Also, we
determined
that dogs whose tumors responded to PALLADIA experienced an improved
quality of life, said Dr. London, who has helped Pfizer Animal Health
Veterinary Medicine Research & Development to develop PALLADIA
since 2000.
Further Information about PALLADIA
PALLADIA can be administered in a veterinary clinic or in the home by a dogs
caregiver. PALLADIA is not for human use and is only available
in the U.S. Adverse events with PALLADIA can be serious but most are mild to
moderate and are generally manageable. The most common side effects of
PALLADIA involve the gastrointestinal tract and signs include diarrhea,
decreased appetite, lethargy and vomiting. Life-threatening adverse events
are
rare but possible and early recognition is critical. Children should not
come
in contact with PALLADIA. In addition, all individuals, including children
and pregnant women, should avoid direct contact with broken or partially-
dissolved PALLADIA tablets or biological waste from dogs treated with
PALLADIA. For specific dosing and prescribing information, visit
<
http://www.palladia -pi.com/> www.palladia- pi.com